ライフサイエンスコーパス: melanoma-specific survival

1 s of this analysis were overall survival and melanoma-specific survival.

2 ant disease control and resulted in enhanced melanoma-specific survival.

3 points were RFS, overall survival (OS), and melanoma-specific survival.

4 The primary end point was melanoma-specific survival.

5 cell invasion are robust predictors of poor melanoma-specific survival.

6 e patterns, including conditional rates, and melanoma-specific survival.

7 comes were local recurrence, metastasis, and melanoma-specific survival.

8 enotypes and assessed their association with melanoma-specific survival.

9 Recurrence, overall survival, and melanoma-specific survival.

10 diagnosis of MIS was evaluated using 15-year melanoma-specific survival, 15-year relative survival (i

11 dissection was not associated with increased melanoma-specific survival among 1934 patients with data

12 prognostic information but did not increase melanoma-specific survival among patients with melanoma

13 , including results for overall survival and melanoma-specific survival, as well as durability of res

14 ults from prior studies.OBJECTIVE To compare melanoma-specific survival between patients with histopa

15 The 5-year melanoma specific survival calculated from the date of t

16 Melanoma-specific survival estimates to December 31, 200

17 to extend disease free survival and increase melanoma-specific survival for patients with early nodal

18 d prolongs distant disease-free survival and melanoma-specific survival for patients with nodal metas

19 Patients with CIMP melanomas had worse melanoma-specific survival (hazard ratio = 11.84; confid

20 mitotic rate was a significant predictor of melanoma-specific survival (Hazard Ratio [HR] = 1.2, 95%

21 tus was an independent prognostic factor for melanoma-specific survival (hazard ratio [HR] = 1.34; 95

22 tasis, 0.62; P=0.02) and the 10-year rate of melanoma-specific survival (hazard ratio for death from

23 mph-node biopsy is associated with increased melanoma-specific survival (i.e., survival until death f

24 whereas a marker in EBF1 was associated with melanoma-specific survival in advanced-stage patients (r

25 (P<0.0001) and significantly associated with melanoma-specific survival in both stage III (P<0.0001)

26 all six genes were significant in predicting melanoma specific survival (MSS) in a univariate analysi

27 rt to assess recurrence-free survival (RFS), melanoma-specific survival (MSS) and overall survival (O

28 Conditional melanoma-specific survival (MSS) estimates up to 5 years

29 The 5-year melanoma-specific survival (MSS) for ulcerated and nonul

30 onfirmed objective response rate (cORR), and melanoma-specific survival (MSS) per investigator; overa

31 age III cohort versus the AJCCv8 cohort, the melanoma-specific survival (MSS) rates at 5 years were 6

32 Melanoma-specific survival (MSS) was not significantly d

33 d rates of 10-year overall survival (OS) and melanoma-specific survival (MSS) were 82% and 94%, respe

34 status, recurrence-free survival (RFS), and melanoma-specific survival (MSS) were analyzed.

35 Disease-free survival, melanoma-specific survival (MSS), and overall survival.

36 nd clinical outcomes: overall survival (OS), melanoma-specific survival (MSS), and recurrence-free su

37 l lymph node (SLN) had significantly reduced melanoma-specific survival (MSS), DFS, regional node rec

38 G) of these loci had markedly reduced OS and melanoma-specific survival (MSS).

39 nce of CTC status for disease recurrence and melanoma-specific survival (MSS).

40 o compare recurrence-free survival (RFS) and melanoma-specific survival (MSS).

41 Melanoma-specific survival (MSS; descriptive analysis),

42 sociated with poorer overall (OS; P < .001), melanoma-specific survival (MSS; P = .0025), and disease

43 Children with melanoma had a 5-year melanoma-specific survival of 93.6% (95% CI, 91.9 to 94.

44 Clinicopathologic predictors and melanoma-specific survival of histologically amelanotic

45 Melanoma-specific survival of patients with current, for

46 in the recurrence rate, overall survival, or melanoma-specific survival of patients with MIS treated

47 Tumor characteristics and melanoma-specific survival of primary melanoma by NRAS a

48 The 5-year uveal melanoma-specific survival probability was 82.9% (95% CI

49 ntermediate-thickness melanomas, the 10-year melanoma-specific survival rate was 62.1 +/- 4.8% among

50 treatment-related difference in the 10-year melanoma-specific survival rate was seen in the overall

51 1), distant-metastasis-free (P = 0.029), and melanoma-specific survival rates (P = 0.029) in CM.

52 in stage IA compared with the AJCCv8 cohort, melanoma-specific survival rates at 10 years were 95.1%-

53 The melanoma-specific survival rates in the two CMMR cohorts

54 The corresponding 20-year melanoma-specific survival rates were 91.9% (95% CI, 91.

55 In 2017, 10-year melanoma-specific survival rates were 98% to 94% for sta

56 Factors predicting melanoma-specific survival rates were analyzed using the

57 Melanoma-specific survival rates were not different betw

58 Five-year melanoma-specific survival rates were similar in the two

59 , ulceration) yields a wide range of 10-year melanoma-specific survival rates.

60 ial, including results for overall survival, melanoma-specific survival, relapse-free survival, and d

61 There was no significant difference in melanoma-specific survival (reported as hazard ratios [9

62 sults suggest that the MAPK pathway mediates melanoma-specific survival signaling by differentially r

63 patients with a brisk TIL score had improved melanoma-specific survival than those with a nonbrisk sc

64 Median melanoma-specific survival was 51.9 months (95% CI 30.0-

65 ive and progression-free at 3 years, 10-year melanoma-specific survival was 96% with nivolumab plus i

66 The 15-year melanoma-specific survival was 98.4% (95% CI, 98.3%-98.5

67 Median melanoma-specific survival was more than 120 months with

68 However, melanoma-specific survival was significantly poorer for

69 Melanoma-specific survival was significantly worse for p

70 ol analysis, the mean (+/-SE) 3-year rate of melanoma-specific survival was similar in the dissection

71 (AJCC-8) melanoma staging system focuses on melanoma-specific survival, we developed a multivariable

72 Progression-free survival (PFS) and melanoma-specific survival were analyzed, and a Cox prop

73 fied PFS on second-course pembrolizumab, and melanoma-specific survival were exploratory.

74 or characteristics, disease progression, and melanoma-specific survival were recorded.